Your browser doesn't support javascript.
loading
Anti-TIF1γ antibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review.
Sakurai, Takuya; Takahashi, Junichiro; Komatsu, Teppei; Mitsumura, Hidetaka; Iguchi, Yasuyuki.
Afiliação
  • Sakurai T; Department of Cardiology, The Jikei University School of Medicine, Tokyo, Japan.
  • Takahashi J; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
  • Komatsu T; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
  • Mitsumura H; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
  • Iguchi Y; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
Mod Rheumatol Case Rep ; 7(2): 416-421, 2023 06 19.
Article em En | MEDLINE | ID: mdl-36715286
We report a case of anti-transcriptional intermediary factor 1γ antibody-positive dermatomyositis following nivolumab treatment. The patient was successfully treated with pulse steroid therapy and high-dose intravenous immunoglobulin, followed by oral glucocorticoid treatment. Immune checkpoint inhibitors, such as nivolumab, may induce not only myositis as an immune-related adverse event but also dermatomyositides as a paraneoplastic syndrome by distracting immune tolerance. Differentiating between pathologies is warranted if patients develop myositis after immune checkpoint inhibitor administration.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Dermatomiosite / Carcinoma de Células Escamosas do Esôfago / Miosite Tipo de estudo: Diagnostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Dermatomiosite / Carcinoma de Células Escamosas do Esôfago / Miosite Tipo de estudo: Diagnostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article